We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group | AQSE:RENE.GB | Aquis Stock Exchange | Ordinary Share | GB00BF5G6K95 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.75 | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMRENE
RNS Number : 8537R
ReNeuron Group plc
14 December 2016
14 December 2016 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Director Share Purchase
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 14 December 2016 that, on the same day, Olav Hellebø, the Company's Chief Executive Officer, acquired 346,644 ordinary shares of 1p each ("Ordinary Shares") at a price of 2.8848p per share.
Following this share purchase, Olav Hellebø's total beneficial interest in the Company is 669,422 Ordinary Shares, representing 0.021 per cent of the Company's total voting rights.
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400 Olav Hellebø, Chief Executive Officer Michael Hunt, Chief Financial Officer Buchanan +44 (0) 20 7466 5000 Mark Court, Sophie Cowles, Stephanie Watson Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600 Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to purchase of Ordinary Shares)
1 Details of the person discharging managerial responsibilities / person closely associated --- ------------------------------------------------------------ a) Name Olav Hellebø --- ------------------------ ---------------------------------- 2 Reason for the notification --- ------------------------------------------------------------ a) Position/status Chief Executive Officer --- ------------------------ ---------------------------------- b) Initial notification Initial notification /Amendment --- ------------------------ ---------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ------------------------------------------------------------ a) Name ReNeuron Group plc --- ------------------------ ---------------------------------- b) LEI N/A --- ------------------------ ---------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------ a) Description of Ordinary Shares 0.01p the financial instrument, type RENE - GB00B0DZML60 of instrument Identification code --- ------------------------ ---------------------------------- b) Nature of the Purchase of ordinary shares transaction --- ------------------------ ---------------------------------- c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- 2.8848p 346,644 --------- ---------- --- ------------------------ ---------------------------------- d) Aggregated information N/A --- ------------------------ ---------------------------------- e) Date of the transaction 14 December 2016 --- ------------------------ ---------------------------------- f) Place of the London Stock Exchange, AIM Market transaction --- ------------------------ ----------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUSRURNKAUAAA
(END) Dow Jones Newswires
December 14, 2016 07:15 ET (12:15 GMT)
1 Year Reneuron Chart |
1 Month Reneuron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions